Adam

life changing

61% of astronauts on ISS missions reactivate dormant viruses while in outer space (e.g. EBV, VZV, CMV) -- and the full immune cascade driving this still isn't fully understood What's exciting is the Artemis II crew is now flying with personalized organ chips built from their own bone marrow cells, which could finally help us understand how and why these viruses get reactivated at the cellular level I post a lot about immune function and mitochondrial health -- and I believe the viral reactivation in this case is directly related to something going wrong with the body's energy systems, specifically to the mitochondria Microgravity triggers oxidative stress, damages mitochondrial function, and suppresses immune cells. The NK cells and T-cells that normally keep viruses in check essentially shut down What makes this interesting beyond space is that a similar pattern shows up in ME/CFS, Lyme, and long COVID patients Same thing here, mitochondrial dysfunction, immune suppression, and dormant viruses wake back up because the body's ability to keep them suppressed breaks down Maybe with this chip we'll be able to pinpoint the exact moment the body's defenses goes haywire, or maybe we'll find a better biomarker which can point a specific mechanism causing the immune dysfunction Two NASA-funded health studies I'm tracking (highlighted in yellow) - Blaber Lab (mitochondrial dysfunction in spaceflight) - Dr. Iyer (mitochondrial oxidative stress) Both seem like they're building toward the same question from different angles

Why do Navy seals always birth girls?

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known. The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system. The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma. Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness. The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.